MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, announces it has initiated plans to separate the
https://youtu.be/8MSNhYapsRI Highlights: Reported positive results of independent review of utility for MagSense® HER2 breast cancer detection Announced plan to advance MagSense® HER2 program to multi-site
In accordance with Listing Rule 3.17, Imagion Biosystems Limited attaches a copy of the following documents: 1. Letter to Shareholders regarding arrangements for the Annual
Imagion Biosystems (ASX:IBX) is a biotech company dedicated to improving healthcare through the earlier detection of cancer and other diseases. We are using our proprietary
We are continuing the momentum from our positive phase 1 trial results and are pleased to have recently released our latest updates in our April
Pitt Street Research has published a 27-page overview report on Imagion Biosystems, Limited. This detailed report includes close examinations of the company’s business and investment
We’re on a mission to make cancer more detectable.
